Retinopathy of prematurity (ROP) is a significant cause of potentially preventable blindness
in preterm infants worldwide. It is a disease caused by abnormal retinal vascularization that …

Ocular diseases are a growing global concern and have a significant impact on the quality of
life. Cataracts, glaucoma, age-related macular degeneration, and diabetic retinopathy are …

Objective This study aimed to evaluate the preference for antivascular endothelial growth
factor (anti-VEGF) versus laser ablation therapy as primary and additional treatment in …

This study aimed to determine whether the state of retinal vascularization after anti-vascular
endothelial growth factor (anti-VEGF) injection can help predict the risk of reactivated …

Although intravitreal anti–vascular endothelial growth factor (VEGF) therapy is effective in
the management of retinopathy of prematurity (ROP), reactivations following treatment are …

This paper assesses the preferred treatment patterns for retinopathy of prematurity (ROP)
and examine trends in anti-vascular endothelial growth factor (VEGF) use for ROP. Methods …

Zusammenfassung Hintergrund Die Frühgeborenenretinopathie („retinopathy of prematurity
“[ROP]) ist eine der häufigsten Ursachen für eine hochgradige Sehbehinderung oder …

Purpose: To assess the efficacy of intravitreal ranibizumab (IVR) monotherapy in type 1
retinopathy of prematurity compared to aggressive retinopathy of prematurity (A-ROP) in …

Retinal blood vessels of premature infants begin to form from the optic nerve head to the
periphery according to the gestational age, and when the formation of retinal blood vessels …

This study aimed to determine whether the state of retinal vascularization after anti-vascular
endothelial growth factor (anti-VEGF) injection can help predict the risk of recurrence of …